The effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapy

BJU International

Volumn 98, Issue 4, 2006, Pages 770-772

  Uchida, Toyoaki ^a   Illing, Rowland O ^b,c   Cathcart, Paul J ^c   Emberton, Mark ^b,c  

^a TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^b INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^c ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

Author keywords

Ablation; Androgen suppression; Focused ultrasound; HIFU; Outcome; Prostate

Indexed keywords

ANDROGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; DEMOGRAPHY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT FAILURE; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 33748574925     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06369.x     Document Type: Article

References (12)

1. Cancer Research UK. UK prostate cancer incidence statistics 2002. Available at: http://info.cancerresearchuk.org/cancerstats/types/prostate/ incidence/. Accessed April 2006
2. Ahmed S, Lindsey B, Davies J. Emerging minimally invasive techniques for treating localized prostate cancer. BJU Int 2005; 96: 1230-4
3. Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer 2005; 5: 321-7
4. Gelet A, Chapelon JY, Bouvier R et al. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 2000; 14: 519-28
5. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006; 97: 56-61
6. Ash D, Al-Qaisieh B, Bottomley D, Carey B, Joseph J. The impact of hormone therapy on post-implant dosimetry and outcome following iodine-125 implant monotherapy for localised prostate cancer. Radiother Oncol 2005; 75: 303-6
7. Armas OA, Aprikian AG, Melamed J et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994; 18: 979-91
8. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995; 55: 3346-51
9. Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991; 68: 821-8
10. Illing RO, Leslie TA, Kennedy JE, Calleary JG, Ogden CW, Emberton M. Visually directed HIFU for organ confined prostate cancer - a proposed standard for the conduct of therapy. BJU Int; in press
11. Smart OC, Hindley JT, Regan L, Gedroyc WM. Magnetic resonance guided focused ultrasound surgery of uterine fibroids - the tissue effects of GnRH agonist pre-treatment. Eur J Radiol 2006; Epub ahead of print
12. Janoff DM, Peterson C, Mongoue-Tchokote S et al. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int 2005; 96: 503-7